These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 29581547)

  • 1. Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma.
    Zhang X; Lee HC; Shirazi F; Baladandayuthapani V; Lin H; Kuiatse I; Wang H; Jones RJ; Berkova Z; Singh RK; Lu J; Qian Y; Raina K; Coleman KG; Crews CM; Li B; Wang H; Hailemichael Y; Thomas SK; Wang Z; Davis RE; Orlowski RZ
    Leukemia; 2018 Oct; 32(10):2224-2239. PubMed ID: 29581547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in
    Díaz T; Rodríguez V; Lozano E; Mena MP; Calderón M; Rosiñol L; Martínez A; Tovar N; Pérez-Galán P; Bladé J; Roué G; de Larrea CF
    Haematologica; 2017 Oct; 102(10):1776-1784. PubMed ID: 28751557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The novel protein homeostatic modulator BTX306 is active in myeloma and overcomes bortezomib and lenalidomide resistance.
    Zou J; Jones RJ; Wang H; Kuiatse I; Shirazi F; Manasanch EE; Lee HC; Sullivan R; Fung L; Richard N; Erdman P; Torres E; Hecht D; Lam I; McElwee B; Chourasia AH; Chan KWH; Mercurio F; Stirling DI; Orlowski RZ
    J Mol Med (Berl); 2020 Aug; 98(8):1161-1173. PubMed ID: 32632752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma.
    Lee HC; Wang H; Baladandayuthapani V; Lin H; He J; Jones RJ; Kuiatse I; Gu D; Wang Z; Ma W; Lim J; O'Brien S; Keats J; Yang J; Davis RE; Orlowski RZ
    Br J Haematol; 2017 Apr; 177(1):80-94. PubMed ID: 28369725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.
    Gopalakrishnan R; Matta H; Tolani B; Triche T; Chaudhary PM
    Oncogene; 2016 Apr; 35(14):1797-810. PubMed ID: 26119939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple myeloma: Combination therapy of BET proteolysis targeting chimeric molecule with CDK9 inhibitor.
    Lim SL; Xu L; Han BC; Shyamsunder P; Chng WJ; Koeffler HP
    PLoS One; 2020; 15(6):e0232068. PubMed ID: 32559187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myeloma.
    Crawford LJ; Campbell DC; Morgan JJ; Lawson MA; Down JM; Chauhan D; McAvera RM; Morris TC; Hamilton C; Krishnan A; Rajalingam K; Chantry AD; Irvine AE
    Oncogene; 2020 Jul; 39(27):5001-5014. PubMed ID: 32523091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a novel c-Myc inhibitor with antitumor effects on multiple myeloma cells.
    Yao R; Sun X; Xie Y; Sun X; Yao Y; Li H; Li Z; Gao J; Xu K
    Biosci Rep; 2018 Oct; 38(5):. PubMed ID: 30068698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care.
    Paíno T; Garcia-Gomez A; González-Méndez L; San-Segundo L; Hernández-García S; López-Iglesias AA; Algarín EM; Martín-Sánchez M; Corbacho D; Ortiz-de-Solorzano C; Corchete LA; Gutiérrez NC; Maetos MV; Garayoa M; Ocio EM
    Clin Cancer Res; 2017 Jan; 23(1):225-238. PubMed ID: 27440267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.
    Rhyasen GW; Hattersley MM; Yao Y; Dulak A; Wang W; Petteruti P; Dale IL; Boiko S; Cheung T; Zhang J; Wen S; Castriotta L; Lawson D; Collins M; Bao L; Ahdesmaki MJ; Walker G; O'Connor G; Yeh TC; Rabow AA; Dry JR; Reimer C; Lyne P; Mills GB; Fawell SE; Waring MJ; Zinda M; Clark E; Chen H
    Mol Cancer Ther; 2016 Nov; 15(11):2563-2574. PubMed ID: 27573426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimyeloma activity of bromodomain inhibitors on the human myeloma cell line U266 by downregulation of MYCL.
    Suzuki K; Yamamoto K; Arakawa Y; Yamada H; Aiba K; Kitagawa M
    Anticancer Drugs; 2016 Sep; 27(8):756-65. PubMed ID: 27276402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity.
    Que W; Chen J; Chuang M; Jiang D
    APMIS; 2012 Mar; 120(3):195-203. PubMed ID: 22339676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.
    Abruzzese MP; Bilotta MT; Fionda C; Zingoni A; Soriani A; Vulpis E; Borrelli C; Zitti B; Petrucci MT; Ricciardi MR; Molfetta R; Paolini R; Santoni A; Cippitelli M
    J Hematol Oncol; 2016 Dec; 9(1):134. PubMed ID: 27903272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteolysis targeting chimeric molecules as therapy for multiple myeloma: efficacy, biomarker and drug combinations.
    Lim SL; Damnernsawad A; Shyamsunder P; Chng WJ; Han BC; Xu L; Pan J; Pravin DP; Alkan S; Tyner JW; Koeffler HP
    Haematologica; 2019 Jun; 104(6):1209-1220. PubMed ID: 30606790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies.
    Stubbs MC; Burn TC; Sparks R; Maduskuie T; Diamond S; Rupar M; Wen X; Volgina A; Zolotarjova N; Waeltz P; Favata M; Jalluri R; Liu H; Liu XM; Li J; Collins R; Falahatpisheh N; Polam P; DiMatteo D; Feldman P; Dostalik V; Thekkat P; Gardiner C; He X; Li Y; Covington M; Wynn R; Ruggeri B; Yeleswaram S; Xue CB; Yao W; Combs AP; Huber R; Hollis G; Scherle P; Liu PCC
    Clin Cancer Res; 2019 Jan; 25(1):300-311. PubMed ID: 30206163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents.
    Klingbeil O; Lesche R; Gelato KA; Haendler B; Lejeune P
    Cell Death Dis; 2016 Sep; 7(9):e2365. PubMed ID: 27607580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.
    Bjorklund CC; Lu L; Kang J; Hagner PR; Havens CG; Amatangelo M; Wang M; Ren Y; Couto S; Breider M; Ning Y; Gandhi AK; Daniel TO; Chopra R; Klippel A; Thakurta AG
    Blood Cancer J; 2015 Oct; 5(10):e354. PubMed ID: 26430725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells.
    Zaman S; Shentu S; Yang J; He J; Orlowski RZ; Stellrecht CM; Gandhi V
    Neoplasia; 2015 Mar; 17(3):289-300. PubMed ID: 25810013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FGF Trapping Inhibits Multiple Myeloma Growth through c-Myc Degradation-Induced Mitochondrial Oxidative Stress.
    Ronca R; Ghedini GC; Maccarinelli F; Sacco A; Locatelli SL; Foglio E; Taranto S; Grillo E; Matarazzo S; Castelli R; Paganini G; Desantis V; Cattane N; Cattaneo A; Mor M; Carlo-Stella C; Belotti A; Roccaro AM; Presta M; Giacomini A
    Cancer Res; 2020 Jun; 80(11):2340-2354. PubMed ID: 32094301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma.
    Munugalavadla V; Mariathasan S; Slaga D; Du C; Berry L; Del Rosario G; Yan Y; Boe M; Sun L; Friedman LS; Chesi M; Leif Bergsagel P; Ebens A
    Oncogene; 2014 Jan; 33(3):316-25. PubMed ID: 23318440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.